Thiazolidinediones and Glucagon‐Like Peptide‐1 Receptor Agonists and the Risk of Nonalcoholic Fatty Liver Disease: A Cohort Study-Reference-Cited by-同舟云学术

Thiazolidinediones and Glucagon‐Like Peptide‐1 Receptor Agonists and the Risk of Nonalcoholic Fatty Liver Disease: A Cohort Study

Published:2021-08-22 Issue:5 Volume:74 Page:2467-2477
ISSN:0270-9139
Container-title:Hepatology
language:en
Short-container-title:Hepatology

Author:

Dalem Judith¹²^ORCID,Driessen Johanna H. M.¹²³⁴,Burden Andrea M.⁵,Stehouwer Coen D. A.²⁶,Klungel Olaf H.³,Vries Frank¹²³,Brouwers Martijn C. G. J.²⁷^ORCID

Affiliation:

1. Department of Clinical Pharmacy & Toxicology Maastricht University Medical Centre+ Maastricht the Netherlands

2. CARIM School for Cardiovascular Disease Maastricht University Maastricht the Netherlands

3. Division of Pharmacoepidemiology and Clinical Pharmacology Utrecht Institute of Pharmaceutical Sciences Utrecht the Netherlands

4. NUTRIM School for Nutrition and Translational Research in MetabolismMaastricht University Maastricht the Netherlands

5. Department of Chemistry and Applied Biosciences Institute of Pharmaceutical Sciences ETH Zurich Zurich Switzerland

6. Department of Internal Medicine Maastricht University Medical Centre+ Maastricht the Netherlands

7. Department of Internal Medicine Division of Endocrinology and Metabolic Disease Maastricht University Medical Centre+ Maastricht the Netherlands

Publisher

Wiley

Subject

Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/hep.32012

Reference55 articles.

1. The epidemiology of non-alcoholic fatty liver disease

2. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability‐adjusted life‐years for 29 cancer groups, 1990 to 2017: a systematic analysis for the Global Burden of Disease Study;Fitzmaurice C;JAMA Oncol,1990

3. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study

4. A Placebo-Controlled Trial of Pioglitazone in Subjects with Nonalcoholic Steatohepatitis

5. Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Current strategies for nonalcoholic fatty liver disease treatment (Review);International Journal of Molecular Medicine;2024-08-08

2. The Relationship between Pathogenesis and Possible Treatments for the MASLD-Cirrhosis Spectrum;International Journal of Molecular Sciences;2024-04-16

3. Association of glucagon-like peptide-1 receptor agonists with serious liver events among patients with type 2 diabetes: A Scandinavian cohort study;Hepatology;2024-02-09

4. Association between hypoglycemic agent use and the risk of occurrence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus;PLOS ONE;2023-11-22

5. Lower risks of cirrhosis and hepatocellular carcinoma with GLP‐1RAs in type 2 diabetes: A nationwide cohort study using target trial emulation framework;Journal of Internal Medicine;2023-11-22